Berger Montague Encourages Gossamer Bio Investors to Join Class Action Over Securities Fraud Claims

In a critical move for investors of Gossamer Bio, Inc. (NASDAQ: GOSS), the renowned national law firm Berger Montague has officially announced a class action lawsuit targeting the biopharmaceutical company. This action comes in the wake of alarming developments for shareholders who acquired Gossamer stock over the defined period from June 16, 2025, to February 20, 2026, which witnessed an unexpected plunge in the company’s stock price amid allegations of securities fraud.

Background of the Case

Gossamer Bio, based in San Diego, California, operates in the clinical-stage biopharmaceutical sector, focusing on therapies aimed at combating immuno-inflammatory diseases and other illnesses. A pivotal event occurred on February 23, 2026, when the company disclosed that its Phase 3 PROSERA study — specifically tailored to evaluate the effectiveness of seralutinib for treating pulmonary arterial hypertension (PAH) — failed to meet its primary goals, particularly concerning the six-minute walk distance (6MWD) metric.

This announcement sharply contradicts earlier expectations and led Gossamer's shares to plummet by over 80% on the same day. Investors were caught off guard, facing significant financial losses as a result of the company’s disclosures regarding the trial outcome and potential operational shortcomings.

What Investors Need to Know

As of the 2026 timeline, shareholders who purchased Gossamer securities within the specified class period are encouraged to make inquiries related to the ongoing lawsuit. Berger Montague is soliciting interested investors to step forward, with a deadline set for June 1, 2026, for any shareholder wishing to assume the role of lead plaintiff representative in this class action.

To assist affected stakeholders in understanding their rights and options, Berger Montague has provided clear channels for communication. Investors can reach out to Andrew Abramowitz or Caitlin Adorni via telephone or email for immediate guidance on their positions and avenues of recourse.

Continuing Legal Overview

The legal firm behind this action, Berger Montague, has built a reputation as one of the leading law practices in the United States, often spearheading complex civil litigation and securities cases. With over 55 years of experience, the firm has successfully recovered billions for clients through various significant legal actions.

The firm is well-versed in matters involving class actions and mass torts, which include issues across several sectors such as consumer protection, environmental law, and corporate disputes. Their expertise positions them uniquely to handle the complexities involved in this case against Gossamer Bio.

Conclusion and Next Steps

For Gossamer Bio shareholders, the ongoing class action represents both a means to potentially recuperate losses incurred during the tumultuous period of the stock’s depreciation and a call to action for collective accountability in corporate governance.

In summation, if you are a shareholder of Gossamer Bio who purchased shares during the stipulated timeframe, it would be prudent to consider your options regarding this significant class action lawsuit. To further explore your rights and the potential implications of the ongoing case, do not hesitate to connect with Berger Montague for detailed instructions and legal guidance.

This represents a pivotal moment for Gossamer Bio investors as they navigate a challenging fall-out from the recent securities fraud allegations, with Berger Montague advocating on their behalf in the pursuit of justice for their substantial and unexpected financial losses.